Drug Name |
Octreotide acetate |
Drug ID |
BADD_D01595 |
Description |
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501]
Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528] |
Indications and Usage |
For treatment of acromegaly and reduction of side effects from cancer chemotherapy |
Marketing Status |
Prescription; Discontinued |
ATC Code |
H01CB02 |
DrugBank ID |
DB00104
|
KEGG ID |
D02250
|
MeSH ID |
D015282
|
PubChem ID |
6917964
|
TTD Drug ID |
D02XIY
|
NDC Product Code |
59651-004; 0078-0180; 76177-119; 67457-245; 65015-840; 55463-0035; 25021-451; 0703-3333; 0703-3301; 63415-0065; 67457-246; 0078-0182; 0703-3311; 0641-6174; 0078-0818; 66558-0192; 63323-378; 0641-6177; 63323-376; 0703-3321; 63323-379; 63629-8831; 0641-6176; 0641-6175; 66558-0180; 65129-1049; 25021-452; 0078-0811; 63557-0019; 25021-454; 63323-377; 25021-455; 67457-239; 0703-3343; 0641-6178; 25021-453; 52416-123; 0078-0825; 32861-0005; 0078-0181 |
Synonyms |
Octreotide | SMS 201-995 | SMS 201 995 | SMS 201995 | SM 201-995 | SM 201 995 | SM 201995 | Sandoz 201-995 | Sandoz 201 995 | Sandoz 201995 | Compound 201-995 | Compound 201 995 | Compound 201995 | SAN 201-995 | SAN 201 995 | SAN 201995 | Octreotide Acetate | Octreotide Acetate Salt | Sandostatine | Sandostatin |